Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Itron Shares Plunge Despite Strong Quarterly Performance

Robert Sasse by Robert Sasse
October 31, 2025
in Analysis, Earnings, Tech & Software
0
Itron Stock
0
SHARES
22
VIEWS
Share on FacebookShare on Twitter

Itron experienced a dramatic sell-off in after-hours trading yesterday, with its stock price collapsing by over 13%. This sharp decline occurred even as the company reported quarterly earnings that surpassed analyst expectations. The market’s negative reaction was primarily driven by disappointing revenue guidance and a subsequent analyst downgrade issued this morning.

Market Punishes Conservative Outlook

The technology company delivered an adjusted earnings per share of $1.54, exceeding the projected $1.48. Revenue reached $582 million, also beating estimates, though this figure represents a 5% decrease compared to the same period last year.

Despite these results, investor sentiment turned sharply negative, pushing shares down as much as 14.9% to $117.59. The sell-off was triggered by several factors:
* A modest downward revision to full-year revenue guidance, now projected between $2.35-2.36 billion
* Cautious fourth-quarter revenue expectations of $555-565 million
* Ongoing delays in project implementation timelines

Operational Strengths Overshadowed by Downgrade

Adding pressure to the stock, financial services firm Baird downgraded Itron from “Outperform” to “Neutral” this morning. The analyst simultaneously slashed its price target from $137 to $118 per share.

Should investors sell immediately? Or is it worth buying Itron?

This downgrade came despite several strong operational achievements:
* Gross margins reached an all-time high of 37.7%
* The company generated $113 million in free cash flow
* The order backlog remains substantial at $4.3 billion

Recovery Prospects Hinge on Revenue Growth

The divergence between robust profitability metrics and sluggish revenue growth continues to concern market participants. While management raised its 2025 earnings guidance to $6.84-6.94 per share, the revenue trajectory remains a significant vulnerability.

With the stock currently trading around $108.99, it approaches its 52-week low of $90.11. Upcoming investor conferences in November will provide management with crucial opportunities to address market concerns and potentially restore confidence in the company’s growth narrative.

Ad

Itron Stock: Buy or Sell?! New Itron Analysis from February 7 delivers the answer:

The latest Itron figures speak for themselves: Urgent action needed for Itron investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Itron: Buy or sell? Read more here...

Tags: Itron
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Camping World Stock
Consumer & Luxury

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock
Blockchain

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Next Post
Assembly Biosciences Stock

Clinical Breakthroughs and Financial Risks: Assembly Biosciences at a Crossroads

First Trust BuyWrite Income ETF Stock

Covered Call ETF Faces Market Headwinds Amid Tech Concentration

Travelzoo Stock

Travelzoo Shares Plunge Following Disappointing Quarterly Earnings Report

Recommended

Dare Bioscience Stock

Dare Bioscience Stock: Analysts Project Triple-Digit Upside Potential

4 months ago
Bloom Energy Stock

Fuel Cell Leader Bloom Energy Capitalizes on AI Infrastructure Demand

3 months ago
AI travel

NextTrip Inc Announces Official Transition and Ticker Symbol Change

2 years ago
Genprex Stock

Genprex Shares Plunge Amid Heavy Selling Pressure

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

Trending

Camping World Stock
Consumer & Luxury

Camping World’s New Leadership Faces First Major Test

by Jackson Burston
February 7, 2026
0

All eyes are on Camping World Holdings as it approaches a pivotal quarterly report. This will be...

Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Camping World’s New Leadership Faces First Major Test
  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment
  • Diginex Enters Critical Implementation Phase Following Strategic Moves

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com